Vorapaxar No Help in Ischemic Stroke

ASA 2013 — Honolulu — In patients with a recent history of ischemic stroke, adding the investigational antiplatelet vorapaxar to standard therapy for secondary prevention had no effect on vascular events and increased bleeding, a subanalysis of a randomized trial showed.


< Back to Listings